{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:57:45Z","timestamp":1790657865703,"version":"4.1.0"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"DOI":"10.1038\/s41401-026-01947-x","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:30:48Z","timestamp":1790649048000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Cardio-Onco-Immune Axis: immunopathological mechanisms in the cardiac microenvironment of checkpoint inhibitor-induced myocarditis"],"prefix":"10.1038","author":[{"given":"Lian-ke","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-ying","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-jie","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-lan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-shuai","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"1947_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1680838","volume":"16","author":"J Park","year":"2025","unstructured":"Park J, Sk\u00e5lhegg BS. Combination of PD-1\/PD-L1 and CTLA-4 inhibitors in the treatment of cancer\u2014a brief update. Front Immunol. 2025;16:1680838.","journal-title":"Front Immunol"},{"key":"1947_CR2","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323.","journal-title":"N Engl J Med"},{"key":"1947_CR3","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381:2020\u201331.","journal-title":"N Engl J Med"},{"key":"1947_CR4","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521\u201332.","journal-title":"N Engl J Med"},{"key":"1947_CR5","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jaccao.2022.09.004","volume":"4","author":"S Tan","year":"2022","unstructured":"Tan S, Day D, Nicholls SJ, Segelov E. Immune checkpoint inhibitor therapy in oncology: Current uses and future directions: JACC: Cardio-oncology state-of-the-art review. JACC CardioOncol. 2022;4:579\u201397.","journal-title":"JACC CardioOncol"},{"key":"1947_CR6","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1002\/ijc.35347","volume":"156","author":"A Haslam","year":"2025","unstructured":"Haslam A, Olivier T, Prasad V. How many people in the US are eligible for and respond to checkpoint inhibitors: an empirical analysis. Int J Cancer. 2025;156:2352\u20139.","journal-title":"Int J Cancer"},{"key":"1947_CR7","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19:254\u201367.","journal-title":"Nat Rev Clin Oncol"},{"key":"1947_CR8","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579\u201389.","journal-title":"Lancet Oncol"},{"key":"1947_CR9","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71:1755\u201364.","journal-title":"J Am Coll Cardiol"},{"key":"1947_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002553","volume":"9","author":"I Puzanov","year":"2021","unstructured":"Puzanov I, Subramanian P, Yatsynovich YV, Jacobs DM, Chilbert MR, Sharma UC, et al. Clinical characteristics, time course, treatment, and outcomes of patients with immune checkpoint inhibitor-associated myocarditis. J Immunother Cancer. 2021;9:e002553.","journal-title":"J Immunother Cancer"},{"key":"1947_CR11","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073\u2013126.","journal-title":"J Clin Oncol."},{"key":"1947_CR12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jaccao.2025.02.005","volume":"7","author":"O Itzhaki Ben Zadok","year":"2025","unstructured":"Itzhaki Ben Zadok O, O\u2019Hare MJ, Nohria A. Immune checkpoint inhibitor-related myocarditis with or without concomitant myopathy: clinical findings and cardiovascular outcomes. JACC CardioOncol. 2025;7:252\u201364.","journal-title":"JACC CardioOncol"},{"key":"1947_CR13","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749\u201355.","journal-title":"N Engl J Med"},{"key":"1947_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-14668-x","volume":"25","author":"G Yao","year":"2025","unstructured":"Yao G, Zhang Y, Zhang H, Tang L, Ding C, Zhou X. Immune checkpoint inhibitor-associated myocarditis and pericarditis: a pharmacovigilance study based on the FAERS database. BMC cancer. 2025;25:1294.","journal-title":"BMC cancer"},{"key":"1947_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.835510","volume":"13","author":"H Dong","year":"2022","unstructured":"Dong H, Qi Y, Kong X, Wang Z, Fang Y, Wang J. PD-1\/PD-L1 inhibitor-associated myocarditis: epidemiology, characteristics, diagnosis, treatment, and potential mechanism. Front Pharmacol. 2022;13:835510.","journal-title":"Front Pharmacol"},{"key":"1947_CR16","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391:933.","journal-title":"Lancet"},{"key":"1947_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01070-6","volume":"23","author":"RP Patel","year":"2021","unstructured":"Patel RP, Parikh R, Gunturu KS, Tariq RZ, Dani SS, Ganatra S, et al. Cardiotoxicity of immune checkpoint inhibitors. Curr Oncol Rep. 2021;23:79.","journal-title":"Curr Oncol Rep"},{"key":"1947_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-19460-2","volume":"15","author":"X Cheng","year":"2025","unstructured":"Cheng X, Long L, Li Y, Gan X, Yu P, Zhang X, et al. Prognostic risk factors and a survival prediction model for immune checkpoint inhibitor-related myocarditis in patients with lung cancer: a multicenter study. Sci Rep. 2025;15:35514.","journal-title":"Sci Rep"},{"key":"1947_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.163","volume":"4","author":"J Xue","year":"2025","unstructured":"Xue J, Liu C, Shao J, Wang L, Han Y, Wang J, et al. Predictive value of neutrophil-to-lymphocyte ratio for immune checkpoint inhibitor-related myocarditis among patients treated for non-small-cell lung cancer. Cancer Innov. 2025;4:e163.","journal-title":"Cancer Innov"},{"key":"1947_CR20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00392-023-02327-9","volume":"113","author":"E Haj-Yehia","year":"2024","unstructured":"Haj-Yehia E, Mincu RI, Korste S, Lampe L, Margraf SM, Michel L, et al. High neutrophil-to-lymphocyte ratio is associated with cancer therapy-related cardiovascular toxicity in high-risk cancer patients under immune checkpoint inhibitor therapy. Clin Res Cardiol. 2024;113:301\u201312.","journal-title":"Clin Res Cardiol."},{"key":"1947_CR21","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2147\/OTT.S153290","volume":"11","author":"DB Sacdalan","year":"2018","unstructured":"Sacdalan DB, Lucero JA, Sacdalan DL. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. OncoTargets Ther. 2018;11:955\u201365.","journal-title":"OncoTargets Ther"},{"key":"1947_CR22","first-page":"1290","volume":"52","author":"R Lu","year":"2024","unstructured":"Lu R, Lu J, Liao Y, Luo WJ, Wang M, Lu MJ. Analysis of risk factors and establishment of prediction model for immune checkpoint inhibitor-related myocarditis and major adverse cardiovascular events. Zhonghua xin xue guan bing za zhi. 2024;52:1290\u20135.","journal-title":"Zhonghua xin xue guan bing za zhi"},{"key":"1947_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Guti\u00e9rrez E, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386:24\u201334.","journal-title":"N Engl J Med"},{"key":"1947_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/antib13030059","volume":"13","author":"C Frey","year":"2024","unstructured":"Frey C, Etminan M. Adverse events of PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitors: an analysis of the FDA adverse events database. Antibodies. 2024;13:59.","journal-title":"Antibodies"},{"key":"1947_CR25","doi-asserted-by":"crossref","unstructured":"92. Jahrestagung der Deutschen Gesellschaft f\u00fcr Kardiologie \u2013 Herz- und Kreislaufforschung e.V. (German Cardiac Society) : 08. - 11. April 2026, Congress Center Rosengarten Mannheim. Clin Res Cardiol. 2026;115:683.","DOI":"10.1007\/s00392-026-02870-1"},{"key":"1947_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s44272-025-00034-2","volume":"4","author":"S Zhang","year":"2025","unstructured":"Zhang S, Zhang N, Lin J, Zhao L, Jin H, Gao D, et al. Management of multisystemic iraes associated with atezolizumab\/tiragolumab combination therapy in a patient with lung adenocarcinoma: case report and review. Clin Cancer Bull. 2025;4:1\u20138.","journal-title":"Clin Cancer Bull"},{"key":"1947_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-14546-6","volume":"25","author":"S Xu","year":"2025","unstructured":"Xu S, Song Z, Wang D, Wang E, Wang J. Comparative safety of nivolumab plus ipilimumab versus nivolumab plus relatlimab in advanced melanoma: a pharmacovigilance study based on the FDA adverse event reporting system (FAERS). BMC Cancer. 2025;25:1190.","journal-title":"BMC Cancer"},{"key":"1947_CR28","doi-asserted-by":"crossref","unstructured":"Zito C, Manganaro R, Ciappina G, Spagnolo CC, Racanelli V, Santarpia M, et al. Cardiotoxicity induced by immune checkpoint inhibitors: what a cardio-oncology team should know and do. Cancers. 2022;14:5403.","DOI":"10.3390\/cancers14215403"},{"key":"1947_CR29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007524","volume":"14","author":"GT Giblin","year":"2021","unstructured":"Giblin GT, Dennehy C, Featherstone H, Clarke R, Murphy L, Timlin D, et al. Subclinical myocarditis after combination immune checkpoint inhibitor therapy. Circulation Heart Fail. 2021;14:e007524.","journal-title":"Circulation Heart Fail"},{"key":"1947_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1093383","volume":"10","author":"J Xiao","year":"2023","unstructured":"Xiao J, Li X, Wang X, Guan Y, Liu H, Liang J, et al. Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: a single-center experience. Front Cardiovasc Med. 2023;10:1093383.","journal-title":"Front Cardiovasc Med"},{"key":"1947_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf285","volume":"30","author":"Y Fan","year":"2025","unstructured":"Fan Y, Xu Y, Liu X, Liu G, Zhang B, Wu W, et al. Immune checkpoint inhibitor-related myocarditis: a comprehensive analysis of clinical manifestations and prognostic factors. Oncologist. 2025;30:oyaf285.","journal-title":"Oncologist"},{"key":"1947_CR32","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","volume":"138","author":"C Anquetil","year":"2018","unstructured":"Anquetil C, Salem JE, Lebrun-Vignes B, Johnson DB, Mammen AL, Stenzel W, et al. Immune checkpoint inhibitor-associated myositis: expanding the spectrum of cardiac complications of the immunotherapy revolution. Circulation. 2018;138:743\u20135.","journal-title":"Circulation"},{"key":"1947_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.71763","volume":"14","author":"A Schneider","year":"2026","unstructured":"Schneider A, Jhawar N, Reddy D, Chirila R. Immune checkpoint inhibitor-associated myocarditis with myositis\/myasthenia gravis overlap syndrome: two case reports highlighting early onset, diagnostic uncertainty, and management considerations. Clin Case Rep. 2026;14:e71763.","journal-title":"Clin Case Rep"},{"key":"1947_CR34","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","volume":"140","author":"MP Bonaca","year":"2019","unstructured":"Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019;140:80\u201391.","journal-title":"Circulation"},{"key":"1947_CR35","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1161\/CIRCULATIONAHA.121.056730","volume":"146","author":"H Zhu","year":"2022","unstructured":"Zhu H, Galdos FX, Lee D, Waliany S, Huang YV, Ryan J, et al. Identification of pathogenic immune cell subsets associated with checkpoint inhibitor-induced myocarditis. Circulation. 2022;146:316\u201335.","journal-title":"Circulation"},{"key":"1947_CR36","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/CIRCULATIONAHA.123.062405","volume":"148","author":"LH Lehmann","year":"2023","unstructured":"Lehmann LH, Heckmann MB, Bailly G, Finke D, Procureur A, Power JR, et al. Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis. Circulation. 2023;148:473\u201386.","journal-title":"Circulation"},{"key":"1947_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12246","volume":"11","author":"C Han","year":"2022","unstructured":"Han C, Yang J, Zhang E, Jiang Y, Qiao A, Du Y, et al. Metabolic labeling of cardiomyocyte-derived small extracellular vesicle (sEV) miRNAs identifies miR-208a in cardiac regulation of lung gene expression. J Extracell Vesicles. 2022;11:e12246.","journal-title":"J Extracell Vesicles"},{"key":"1947_CR38","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s10637-025-01575-y","volume":"43","author":"Z Wu","year":"2025","unstructured":"Wu Z, Sun W, Wang C. Clinical characteristics, treatment and prognosis of pembrolizumab-induced myocarditis. Invest N Drugs. 2025;43:885\u201393.","journal-title":"Invest N Drugs"},{"key":"1947_CR39","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s11739-023-03481-8","volume":"19","author":"Y Zhuang","year":"2024","unstructured":"Zhuang Y, An Q, Wang F, Han D, Qiao Z, Jiang Q, et al. The role of circulating biomarkers in predicting the 30-day mortality of immune checkpoint inhibitor-related myocarditis: a retrospective cohort study. Intern Emerg Med. 2024;19:377\u201389.","journal-title":"Intern Emerg Med"},{"key":"1947_CR40","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","volume":"72","author":"VM Ferreira","year":"2018","unstructured":"Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: Expert recommendations. J Am Coll Cardiol. 2018;72:3158\u201376.","journal-title":"J Am Coll Cardiol"},{"key":"1947_CR41","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3390\/jcdd12070270","volume":"12","author":"S Nardin","year":"2025","unstructured":"Nardin S, Ruffilli B, Costantini P, Mollace R, Taglialatela I, Pagnesi M, et al. Navigating cardiotoxicity in immune checkpoint inhibitors: From diagnosis to long-term management. J Cardiovasc Dev Dis. 2025;12:270.","journal-title":"J Cardiovasc Dev Dis"},{"key":"1947_CR42","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","volume":"15","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart Cardiovasc Imaging. 2014;15:1063\u201393.","journal-title":"Eur Heart Cardiovasc Imaging"},{"key":"1947_CR43","first-page":"3394","volume":"103","author":"CH Wang","year":"2023","unstructured":"Wang CH, Lin JY, Wang Y, Chen HY, Wu W, Li J, et al. Clinical characteristics analysis of patients with severe immune checkpoint inhibitor-related myocarditis. Zhonghua Yi Xue Za Zhi. 2023;103:3394\u2013401.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"1947_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-021-00844-1","volume":"22","author":"M Frayberg","year":"2021","unstructured":"Frayberg M, Yung A, Zubiri L, Zlotoff DA, Reynolds KL. What the cardiologist needs to know about cancer immunotherapies and complications. Curr Treat options Oncol. 2021;22:53.","journal-title":"Curr Treat options Oncol"},{"key":"1947_CR45","first-page":"35","volume":"3","author":"L Zhang","year":"2021","unstructured":"Zhang L, Reynolds KL, Lyon AR, Palaskas N, Neilan TG. The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity. JACC: CardioOncol Prim JACC CardioOncol. 2021;3:35\u201347.","journal-title":"JACC: CardioOncol Prim JACC CardioOncol"},{"key":"1947_CR46","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMc1901677","volume":"380","author":"JE Salem","year":"2019","unstructured":"Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, et al. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med. 2019;380:2377\u20139.","journal-title":"N Engl J Med"},{"key":"1947_CR47","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","volume":"13","author":"JE Salem","year":"2023","unstructured":"Salem JE, Bretagne M, Abbar B, Leonard-Louis S, Ederhy S, Redheuil A, et al. Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis. Cancer Discov. 2023;13:1100\u201315.","journal-title":"Cancer Discov"},{"key":"1947_CR48","first-page":"108","volume":"11","author":"S Badaan","year":"2025","unstructured":"Badaan S, Abbass A, Tov S, Bar-Sela G, Bisharat N. How should immune checkpoint inhibitor myocarditis be treated? Cardiooncology. 2025;11:108.","journal-title":"Cardiooncology"},{"key":"1947_CR49","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202400839R","volume":"38","author":"V Kumar","year":"2024","unstructured":"Kumar V, Narisawa M, Cheng XW. Overview of multifunctional Tregs in cardiovascular disease: from insights into cellular functions to clinical implications. FASEB J. 2024;38:e23786.","journal-title":"FASEB J"},{"key":"1947_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1331609","volume":"15","author":"Y Xia","year":"2024","unstructured":"Xia Y, Gao D, Wang X, Liu B, Shan X, Sun Y, et al. Role of Treg cell subsets in cardiovascular disease pathogenesis and potential therapeutic targets. Front Immunol. 2024;15:1331609.","journal-title":"Front Immunol"},{"key":"1947_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013214","volume":"13","author":"R Habib","year":"2025","unstructured":"Habib R, Miller WH, Papadopoulos T, Del Rincon SV, Berger C, Molina MF, et al. JAK inhibitors for the treatment of life-threatening and refractory immune-related adverse events secondary to immune checkpoint inhibitors: a prospective cohort study. J Immunother Cancer. 2025;13:e013214.","journal-title":"J Immunother Cancer"},{"key":"1947_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2026.1752485","volume":"16","author":"Z Huang","year":"2026","unstructured":"Huang Z, Mei X, Zhou Y. The gut microbiota: an emerging therapeutic target for ICI-associated myocarditis. Front Cell Infect Microbiol. 2026;16:1752485.","journal-title":"Front Cell Infect Microbiol"},{"key":"1947_CR53","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abm5663","volume":"15","author":"M Liu","year":"2023","unstructured":"Liu M, Wang X, Du X, Wu W, Zhang Y, Zhang P, et al. Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4- and PD-1-targeted immunotherapy. Sci Transl Med. 2023;15:eabm5663.","journal-title":"Sci Transl Med"},{"key":"1947_CR54","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1200\/JCO.2025.43.16_suppl.2658","volume":"43","author":"TL Lim","year":"2025","unstructured":"Lim TL, Restifo D, Merkin RD, Rouhani SJ, Vilbert M, Peacker B, et al. Examining the relationship between multi-agent immunosuppressive therapy for immune-related adverse events (irAE) and infectious complications. J Clin Oncol. 2025;43:2658\u20132658.","journal-title":"J Clin Oncol"},{"key":"1947_CR55","doi-asserted-by":"publisher","first-page":"e075859","DOI":"10.1136\/bmj-2023-075859","volume":"385","author":"NL Palaskas","year":"2024","unstructured":"Palaskas NL, Ali HJ, Koutroumpakis E, Ganatra S, Deswal A. Cardiovascular toxicity of immune therapies for cancer. BMJ. 2024;385:e075859.","journal-title":"BMJ"},{"key":"1947_CR56","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032620","volume":"13","author":"A Sharma","year":"2024","unstructured":"Sharma A, Alexander G, Chu JH, Markopoulos A, Maloul G, Ayub MT, et al. Immune checkpoint inhibitors and cardiotoxicity: a comparative meta-analysis of observational studies and randomized controlled trials. J Am Heart Assoc. 2024;13:e032620.","journal-title":"J Am Heart Assoc"},{"key":"1947_CR57","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.2147\/JIR.S348464","volume":"15","author":"H Zhang","year":"2022","unstructured":"Zhang H, Lin J, Shen Y, Pan J, Wang C, Cheng L. Protective effect of crocin on immune checkpoint inhibitors-related myocarditis through inhibiting NLRP3-mediated pyroptosis in cardiomyocytes via NF-\u03baB pathway. J Inflamm Res. 2022;15:1653\u201366.","journal-title":"J Inflamm Res"},{"key":"1947_CR58","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1161\/ATVBAHA.117.309575","volume":"37","author":"T van der Heijden","year":"2017","unstructured":"van der Heijden T, Kritikou E, Venema W, van Duijn J, van Santbrink PJ, Sl\u00fctter B, et al. NLRP3 inflammasome inhibition by MCC950 reduces atherosclerotic lesion development in apolipoprotein E-deficient mice: brief report. Arterioscler Thromb Vasc Biol. 2017;37:1457\u201361.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1947_CR59","first-page":"828","volume":"38","author":"GP van Hout","year":"2017","unstructured":"van Hout GP, Bosch L, Ellenbroek GH, de Haan JJ, van Solinge WW, Cooper MA, et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction. Eur Heart J. 2017;38:828\u201336.","journal-title":"Eur Heart J"},{"key":"1947_CR60","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1253\/circj.CJ-16-0949","volume":"81","author":"K Fujisue","year":"2017","unstructured":"Fujisue K, Sugamura K, Kurokawa H, Matsubara J, Ishii M, Izumiya Y, et al. Colchicine improves survival, left ventricular remodeling, and chronic cardiac function after acute myocardial infarction. Circ J. 2017;81:1174\u201382.","journal-title":"Circ J."},{"key":"1947_CR61","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/FJC.0000000000000658","volume":"73","author":"S Toldo","year":"2019","unstructured":"Toldo S, Mauro AG, Cutter Z, Van Tassell BW, Mezzaroma E, Del Buono MG, et al. The NLRP3 inflammasome inhibitor, OLT1177 (dapansutrile), reduces infarct size and preserves contractile function after ischemia- reperfusion injury in the mouse. J Cardiovasc Pharmacol. 2019;73:215\u201322.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1947_CR62","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10557-022-07326-y","volume":"38","author":"YW Li","year":"2024","unstructured":"Li YW, Chen SX, Yang Y, Zhang ZH, Zhou WB, Huang YN, et al. Colchicine inhibits NETs and alleviates cardiac remodeling after acute myocardial infarction. Cardiovasc Drugs Ther. 2024;38:31\u201341.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1947_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1356023","volume":"11","author":"JF Bulnes","year":"2024","unstructured":"Bulnes JF, Gonz\u00e1lez L, Vel\u00e1squez L, Orellana MP, Venturelli PM, Mart\u00ednez G. Role of inflammation and evidence for the use of colchicine in patients with acute coronary syndrome. Front Cardiovasc Med. 2024;11:1356023.","journal-title":"Front Cardiovasc Med"},{"key":"1947_CR64","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1056\/NEJMra1911109","volume":"383","author":"JA Bluestone","year":"2020","unstructured":"Bluestone JA, Anderson M. Tolerance in the age of immunotherapy. N Engl J Med. 2020;383:1156\u201366.","journal-title":"N Engl J Med"},{"key":"1947_CR65","doi-asserted-by":"publisher","first-page":"11646","DOI":"10.3390\/ijms262311646","volume":"26","author":"N Torounidou","year":"2025","unstructured":"Torounidou N, Yerolatsite M, Bouratzis V, Amylidi AL, Zarkavelis G, Naka KK, et al. Fatal myocarditis following adjuvant immunotherapy: a case report and literature review. Int J Mol Sci. 2025;26:11646.","journal-title":"Int J Mol Sci"},{"key":"1947_CR66","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1172\/JCI44583","volume":"121","author":"H Lv","year":"2011","unstructured":"Lv H, Havari E, Pinto S, Gottumukkala RV, Cornivelli L, Raddassi K, et al. Impaired thymic tolerance to \u03b1-myosin directs autoimmunity to the heart in mice and humans. J Clin Invest. 2011;121:1561\u201373.","journal-title":"J Clin Invest"},{"key":"1947_CR67","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/anae.16493","volume":"80","author":"A Malode","year":"2025","unstructured":"Malode A, Makwana B, Patel V, Khadke S, Parikh A, Bagga A, et al. Cardiotoxicity and perioperative considerations in immune checkpoint inhibitor and chimeric antigen receptor T-cell therapy: a narrative review. Anaesthesia. 2025;80:25\u201337.","journal-title":"Anaesthesia"},{"key":"1947_CR68","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.2147\/JIR.S311616","volume":"14","author":"W Zou","year":"2021","unstructured":"Zou W, Lu J, Hao Y. Myocarditis induced by immune checkpoint inhibitors: mechanisms and therapeutic prospects. J Inflamm Res. 2021;14:3077\u201388.","journal-title":"J Inflamm Res"},{"key":"1947_CR69","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","volume":"611","author":"ML Axelrod","year":"2022","unstructured":"Axelrod ML, Meijers WC, Screever EM, Qin J, Carroll MG, Sun X, et al. T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis. Nature. 2022;611:818\u201326.","journal-title":"Nature"},{"key":"1947_CR70","volume":"16","author":"R Gul","year":"2024","unstructured":"Gul R, Shehryar M, Mahboob A, Kareem HK, Inayat A, Safi D, et al. Immune checkpoint inhibitor-associated myocarditis: a literature review. Cureus. 2024;16:e52952.","journal-title":"Cureus"},{"key":"1947_CR71","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.1160062","volume":"322","author":"K Wing","year":"2008","unstructured":"Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322:271\u20135.","journal-title":"Science"},{"key":"1947_CR72","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1084\/jem.20051776","volume":"203","author":"ME Keir","year":"2006","unstructured":"Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006;203:883\u201395.","journal-title":"J Exp Med"},{"key":"1947_CR73","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"key":"1947_CR74","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18:153\u201367.","journal-title":"Nat Rev Immunol"},{"key":"1947_CR75","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartjsupp\/suaf083.020","volume":"27","author":"M Tumani","year":"2025","unstructured":"Tumani M, Brauer J, Heckmann M, Finke D, Frey N, Lehmann L. Cardiomyocyte but not endothelial expression of PD-L1 is required to protect from immune-checkpoint-inhibitor-associated myocarditis (ICIM). Eur Heart J Suppl. 2025;27:suaf083.020.","journal-title":"Eur Heart J Suppl"},{"key":"1947_CR76","doi-asserted-by":"crossref","unstructured":"Yousif LI, Sijtema AG, Appels Y, van den Berg PF, Aboumsallem JP, Manintveld OC, et al. PD-1\/PD-L1 signaling in non-ICI myocarditis. JACC Basic Transl Sci. 2026;11:101539.","DOI":"10.1016\/j.jacbts.2026.101539"},{"key":"1947_CR77","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","volume":"21","author":"AJ Korman","year":"2022","unstructured":"Korman AJ, Garrett-Thomson SC, Lonberg N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discov. 2022;21:509\u201328.","journal-title":"Nat Rev Drug Discov"},{"key":"1947_CR78","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1161\/CIRCRESAHA.106.147124","volume":"101","author":"VA Love","year":"2007","unstructured":"Love VA, Grabie N, Duramad P, Stavrakis G, Sharpe A, Lichtman A. CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes. Circulat Res. 2007;101:248\u201357.","journal-title":"Circulat Res"},{"key":"1947_CR79","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001014","volume":"8","author":"T Maruhashi","year":"2020","unstructured":"Maruhashi T, Sugiura D, Okazaki IM, Okazaki T. Lag-3: From molecular functions to clinical applications. J Immunother Cancer. 2020;8:e001014.","journal-title":"J Immunother Cancer"},{"key":"1947_CR80","doi-asserted-by":"publisher","first-page":"5744","DOI":"10.1073\/pnas.94.11.5744","volume":"94","author":"B Huard","year":"1997","unstructured":"Huard B, Mastrangeli R, Prigent P, Bruniquel D, Donini S, El-Tayar N, et al. Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc Natl Acad Sci USA. 1997;94:5744\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1947_CR81","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41590-022-01176-4","volume":"23","author":"C Guy","year":"2022","unstructured":"Guy C, Mitrea DM, Chou PC, Temirov J, Vignali KM, Liu X, et al. LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation. Nat Immunol. 2022;23:757\u201367.","journal-title":"Nat Immunol"},{"key":"1947_CR82","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1016\/j.cell.2024.06.036","volume":"187","author":"AR Cillo","year":"2024","unstructured":"Cillo AR, Cardello C, Shan F, Karapetyan L, Kunning S, Sander C, et al. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity. Cell. 2024;187:4373\u2013.e15.","journal-title":"Cell"},{"key":"1947_CR83","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/415536a","volume":"415","author":"L Monney","year":"2002","unstructured":"Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415:536\u201341.","journal-title":"Nature"},{"key":"1947_CR84","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","volume":"57","author":"N Joller","year":"2024","unstructured":"Joller N, Anderson AC, Kuchroo VK. LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation. Immunity. 2024;57:206\u201322.","journal-title":"Immunity"},{"key":"1947_CR85","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","volume":"20","author":"Y Wolf","year":"2020","unstructured":"Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2020;20:173\u201385.","journal-title":"Nat Rev Immunol"},{"key":"1947_CR86","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ni1271","volume":"6","author":"C Zhu","year":"2005","unstructured":"Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6:1245\u201352.","journal-title":"Nat Immunol"},{"key":"1947_CR87","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.0105-2896.2010.00903.x","volume":"235","author":"GJ Freeman","year":"2010","unstructured":"Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff RH. TIM genes: A family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev. 2010;235:172\u201389.","journal-title":"Immunol Rev"},{"key":"1947_CR88","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/ni.2376","volume":"13","author":"S Chiba","year":"2012","unstructured":"Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol. 2012;13:832\u201342.","journal-title":"Nat Immunol"},{"key":"1947_CR89","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1002\/eji.201948400","volume":"50","author":"A De Sousa Linhares","year":"2020","unstructured":"De Sousa Linhares A, Kellner F, Jutz S, Zlabinger GJ, Gabius HJ, Huppa JB, et al. TIM-3 and CEACAM1 do not interact in cis and in trans. Eur J Immunol. 2020;50:1126\u201341.","journal-title":"Eur J Immunol"},{"key":"1947_CR90","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.adk4594","volume":"18","author":"H Alamir","year":"2025","unstructured":"Alamir H, Wong CCW, Alsubaiti A, Edmunds GL, Alismail M, Huynh L, et al. TIM3 is a context-dependent coregulator of cytotoxic T cell function. Sci Signal. 2025;18:eadk4594.","journal-title":"Sci Signal"},{"key":"1947_CR91","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10875-024-01685-x","volume":"44","author":"N Pernaa","year":"2024","unstructured":"Pernaa N, Vakkuri A, Arvonen M, Kuismin O, Santaniemi W, Glumoff V, et al. Germline HAVCR2\/TIM-3 checkpoint inhibitor receptor deficiency in recurrent autoinflammatory myocarditis. J Clin Immunol. 2024;44:81.","journal-title":"J Clin Immunol"},{"key":"1947_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110358","volume":"120","author":"J Zhao","year":"2023","unstructured":"Zhao J, Li L, Yin H, Feng X, Lu Q. TIGIT: an emerging immune checkpoint target for immunotherapy in autoimmune disease and cancer. Int Immunopharmacol. 2023;120:110358.","journal-title":"Int Immunopharmacol"},{"key":"1947_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07984-4","volume":"16","author":"H Cui","year":"2025","unstructured":"Cui H, Hamad M, Elkord E. TIGIT in cancer: From mechanism of action to promising immunotherapeutic strategies. Cell Death Dis. 2025;16:664.","journal-title":"Cell Death Dis"},{"key":"1947_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.721333","volume":"8","author":"R Rikhi","year":"2021","unstructured":"Rikhi R, Karnuta J, Hussain M, Collier P, Funchain P, Tang WHW, et al. Immune checkpoint inhibitors mediated lymphocytic and giant cell myocarditis: Uncovering etiological mechanisms. Front Cardiovasc Med. 2021;8:721333.","journal-title":"Front Cardiovasc Med"},{"key":"1947_CR95","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1161\/CIRCULATIONAHA.125.076976","volume":"153","author":"AZ Munir","year":"2026","unstructured":"Munir AZ, Gutierrez A, Krawiec CJ, Manandhar P, Shyani AC, Ma P, et al. CXCR6+ T cells drive immune checkpoint inhibitor myocarditis. Circulation. 2026;153:754\u201368.","journal-title":"Circulation"},{"key":"1947_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1340373","volume":"15","author":"W Jo","year":"2024","unstructured":"Jo W, Won T, Daoud A, \u010cih\u00e1kov\u00e1 D. Immune checkpoint inhibitors associated cardiovascular immune-related adverse events. Front Immunol. 2024;15:1340373.","journal-title":"Front Immunol"},{"key":"1947_CR97","first-page":"82","volume":"10","author":"R Izumi","year":"2024","unstructured":"Izumi R, Hashimoto T, Kisanuki H, Ikuta K, Otsuru W, Asakawa S, et al. Clinical and pathological characteristics of immune checkpoint inhibitor-related fulminant myocarditis. Cardiooncology. 2024;10:82.","journal-title":"Cardiooncology"},{"key":"1947_CR98","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1158\/2326-6066.CIR-24-0011","volume":"12","author":"BA Siddiqui","year":"2024","unstructured":"Siddiqui BA, Palaskas NL, Basu S, Dai Y, He Z, Yadav SS, et al. Molecular pathways and cellular subsets associated with adverse clinical outcomes in overlapping immune-related myocarditis and myositis. Cancer Immunol Res. 2024;12:964\u201387.","journal-title":"Cancer Immunol Res"},{"key":"1947_CR99","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s43018-024-00810-4","volume":"5","author":"F Dimitriou","year":"2024","unstructured":"Dimitriou F, Cheng PF, Saltari A, Schaper-Gerhardt K, Staeger R, Haunerdinger V, et al. A targetable type III immune response with increase of IL-17A expressing CD4+ T\u2009cells is associated with immunotherapy-induced toxicity in melanoma. Nat Cancer. 2024;5:1390\u2013408.","journal-title":"Nat Cancer"},{"key":"1947_CR100","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202400384R","volume":"38","author":"AQ Shang","year":"2024","unstructured":"Shang AQ, Yu CJ, Bi X, Jiang WW, Zhao ML, Sun Y, et al. Blocking CTLA-4 promotes pressure overload-induced heart failure via activating Th17 cells. FASEB J : Off Publ Federation Am Societies Exp Biol. 2024;38:e23851.","journal-title":"FASEB J : Off Publ Federation Am Societies Exp Biol"},{"key":"1947_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-05635-4","volume":"15","author":"H Cao","year":"2025","unstructured":"Cao H, Dai H, Li S, Afzal Z, Wang X, Wen Z, et al. Abnormal gut microbiota may cause PD-1 inhibitor-related cardiotoxicity via suppressing regulatory T cells. Sci Rep. 2025;15:20547.","journal-title":"Sci Rep"},{"key":"1947_CR102","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1093\/cvr\/cvae133","volume":"120","author":"J Yu","year":"2024","unstructured":"Yu J, Long B, Li Z, Tian X, Li D, Long J, et al. Central memory CD4+ T cells play a protective role against immune checkpoint inhibitor-associated myocarditis. Cardiovasc Res. 2024;120:1442\u201355.","journal-title":"Cardiovasc Res"},{"key":"1947_CR103","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.122.062551","volume":"149","author":"P Ma","year":"2024","unstructured":"Ma P, Liu J, Qin J, Lai L, Heo GS, Luehmann H, et al. Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis. Circulation. 2024;149:48\u201366.","journal-title":"Circulation"},{"key":"1947_CR104","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.658","volume":"5","author":"L Yan","year":"2024","unstructured":"Yan L, Wang J, Cai X, Liou YC, Shen HM, Hao J, et al. Macrophage plasticity: signaling pathways, tissue repair, and regeneration. MedComm. 2024;5:e658.","journal-title":"MedComm"},{"key":"1947_CR105","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/CIRCRESAHA.124.325652","volume":"136","author":"YV Huang","year":"2025","unstructured":"Huang YV, Sun Y, Chou H, Wagner N, Vitale MR, Bayer AL, et al. Novel therapeutic approach targeting CXCR3 to treat immunotherapy myocarditis. Circulation Res. 2025;136:473\u201390.","journal-title":"Circulation Res"},{"key":"1947_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114263","volume":"150","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Cao Z, Jia H, Feng Y, Sun X, Wu H, et al. Immune checkpoint inhibitor induces cardiac injury by impairing efferocytosis of macrophages via MerTK cleavage. Int Immunopharmacol. 2025;150:114263.","journal-title":"Int Immunopharmacol"},{"key":"1947_CR107","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41419-020-02778-2","volume":"11","author":"W Xia","year":"2020","unstructured":"Xia W, Zou C, Chen H, Xie C, Hou M. Immune checkpoint inhibitor induces cardiac injury through polarizing macrophages via modulating microRNA-34a\/Kruppel-like factor 4 signaling. Cell death Dis. 2020;11:575.","journal-title":"Cell death Dis"},{"key":"1947_CR108","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.molimm.2024.05.002","volume":"171","author":"J Ma","year":"2024","unstructured":"Ma J, Wang X, Jia Y, Tan F, Yuan X, Du J. The roles of B cells in cardiovascular diseases. Mol Immunol. 2024;171:36\u201346.","journal-title":"Mol Immunol"},{"key":"1947_CR109","doi-asserted-by":"publisher","first-page":"A11983","DOI":"10.1161\/circ.146.suppl_1.11983","volume":"146","author":"D Zlotoff","year":"2022","unstructured":"Zlotoff D, Blum S, Ramesh S, Kernin I, Smith N, Sen P, et al. Abstract 11983: associations between circulating proteins and intracardiac immune populations in immune checkpoint inhibitor-associated myocarditis. Circulation. 2022;146:A11983.","journal-title":"Circulation"},{"key":"1947_CR110","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","volume":"291","author":"H Nishimura","year":"2001","unstructured":"Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291:319\u201322.","journal-title":"Science"},{"key":"1947_CR111","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","volume":"3","author":"EA Tivol","year":"1995","unstructured":"Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3:541\u20137.","journal-title":"Immunity"},{"key":"1947_CR112","doi-asserted-by":"crossref","unstructured":"Cribari F, Khatoun M, Henriquez S, Joulia ML, Colle R, Loirat D, et al. Endomyocardial biopsy in suspected immune checkpoint inhibitor-myocarditis: Histologic spectrum and correlations with clinical and cardiac magnetic resonance features. J Am Heart Assoc. 2026;15:e049145.","DOI":"10.1161\/JAHA.126.049145"},{"key":"1947_CR113","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-024-08105-5","volume":"636","author":"SM Blum","year":"2024","unstructured":"Blum SM, Zlotoff DA, Smith NP, Kernin IJ, Ramesh S, Zubiri L, et al. Immune responses in checkpoint myocarditis across heart, blood and tumour. Nature. 2024;636:215\u201323.","journal-title":"Nature"},{"key":"1947_CR114","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1172\/JCI125916","volume":"129","author":"A Merino","year":"2019","unstructured":"Merino A, Zhang B, Dougherty P, Luo X, Wang J, Blazar BR, et al. Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming. J Clin Invest. 2019;129:3770\u201385.","journal-title":"J Clin Invest."},{"key":"1947_CR115","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/eurheartj\/ehab430","volume":"43","author":"L Michel","year":"2022","unstructured":"Michel L, Helfrich I, Hendgen-Cotta UB, Mincu RI, Korste S, Mrotzek SM, et al. Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. Eur Heart J. 2022;43:316\u201329.","journal-title":"Eur Heart J"},{"key":"1947_CR116","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/8774971","volume":"2023","author":"X Yang","year":"2023","unstructured":"Yang X, Duan X, Xia Z, Huang R, He K, Xiang G. The regulation network of glycerolipid metabolism as coregulators of immunotherapy-related myocarditis. Cardiovasc Ther. 2023;2023:8774971.","journal-title":"Cardiovasc Ther"},{"key":"1947_CR117","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ceb.2014.12.001","volume":"33","author":"V Albert","year":"2015","unstructured":"Albert V, Hall MN. mTOR signaling in cellular and organismal energetics. Curr Opin Cell Biol. 2015;33:55\u201366.","journal-title":"Curr Opin Cell Biol"},{"key":"1947_CR118","first-page":"420","volume":"5","author":"S Galv\u00e1n-Pe\u00f1a","year":"2014","unstructured":"Galv\u00e1n-Pe\u00f1a S, O\u2019Neill LA. Metabolic reprograming in macrophage polarization. Front Immunol. 2014;5:420.","journal-title":"Front Immunol"},{"key":"1947_CR119","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nature11986","volume":"496","author":"GM Tannahill","year":"2013","unstructured":"Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, Goel G, et al. Succinate is an inflammatory signal that induces IL-1\u03b2 through HIF-1\u03b1. Nature. 2013;496:238\u201342.","journal-title":"Nature"},{"key":"1947_CR120","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/s41590-020-0725-2","volume":"21","author":"SA Vardhana","year":"2020","unstructured":"Vardhana SA, Hwee MA, Berisa M, Wells DK, Yost KE, King B, et al. Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. Nat Immunol. 2020;21:1022\u201333.","journal-title":"Nat Immunol"},{"key":"1947_CR121","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.semcancer.2025.12.004","volume":"119","author":"Y Chen","year":"2025","unstructured":"Chen Y, Wang X, Shen Y, Zhang H, Yu C, Cheng L, et al. Immune checkpoint inhibitor-induced myocarditis: Focus on the downstream pathogenic components and potential therapeutics. Semin Cancer Biol. 2025;119:12\u201323.","journal-title":"Semin Cancer Biol"},{"key":"1947_CR122","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s44161-025-00633-1","volume":"4","author":"J Jimenez","year":"2025","unstructured":"Jimenez J, Amrute J, Ma P, Wang X, Das S, Dai R, et al. The immune checkpoint regulator CD40 potentiates myocardial inflammation. Nat Cardiovasc Res. 2025;4:458\u201372.","journal-title":"Nat Cardiovasc Res"},{"key":"1947_CR123","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s00262-024-03899-9","volume":"74","author":"Y Chen","year":"2025","unstructured":"Chen Y, Luo Y, Liu Y, Luo D, Liu A. Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study. Cancer Immunol, Immunother. 2025;74:52.","journal-title":"Cancer Immunol, Immunother"},{"key":"1947_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1232269","volume":"11","author":"V Quagliariello","year":"2024","unstructured":"Quagliariello V, Passariello M, Bisceglia I, Paccone A, Inno A, Maurea C, et al. Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-pro-BNP, interleukin-1\u03b2 and interleukin-6: Biochemical implications in cardio-immuno-oncology. Front Cardiovasc Med. 2024;11:1232269.","journal-title":"Front Cardiovasc Med"},{"key":"1947_CR125","doi-asserted-by":"crossref","unstructured":"Stefanou E, Tsitsinakis G, Karageorgou D, Kole C. Immunotherapy-associated cardiotoxicity: Current insights and future directions for precision cardio-oncology. Cancers. 2025;17:2838.","DOI":"10.3390\/cancers17172838"},{"key":"1947_CR126","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s11912-023-01411-7","volume":"25","author":"A Inno","year":"2023","unstructured":"Inno A, Tarantini L, Parrini I, Spallarossa P, Maurea N, Bisceglia I, et al. Cardiovascular effects of immune checkpoint inhibitors: more than just myocarditis. Curr Oncol Rep. 2023;25:743\u201351.","journal-title":"Curr Oncol Rep"},{"key":"1947_CR127","doi-asserted-by":"publisher","first-page":"e003594","DOI":"10.1136\/jitc-2021-003594","volume":"9","author":"S Boughdad","year":"2021","unstructured":"Boughdad S, Latifyan S, Fenwick C, Bouchaab H, Suffiotti M, Moslehi JJ, et al. 68)Ga-DOTATOC PET\/CT to detect immune checkpoint inhibitor-related myocarditis. J Immunother Cancer. 2021;9:e003594.","journal-title":"J Immunother Cancer"},{"key":"1947_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2026.116693","volume":"239","author":"T Lerchner","year":"2026","unstructured":"Lerchner T, Buehning F, Vogel J, Mincu RI, Zimmer L, Tasdogan A, et al. Diagnostic and prognostic parameters for immune checkpoint inhibitor-related myocarditis: a meta-analysis. Eur J Cancer. 2026;239:116693.","journal-title":"Eur J Cancer"},{"key":"1947_CR129","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2404661121","volume":"121","author":"S Mok","year":"2024","unstructured":"Mok S, A\u011fa\u00e7 \u00c7obano\u011flu D, Liu H, Mancuso JJ, Allison JP. Post-immunotherapy CTLA-4 Ig treatment improves antitumor efficacy. Proc Natl Acad Sci USA. 2024;121:e2404661121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1947_CR130","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1177\/00033197231201929","volume":"75","author":"A Vergara","year":"2024","unstructured":"Vergara A, De Felice M, Cesaro A, Gragnano F, Pariggiano I, Golia E, et al. Immune-checkpoint inhibitor-related myocarditis: where we are and where we will go. Angiology. 2024;75:909\u201320.","journal-title":"Angiology"},{"key":"1947_CR131","doi-asserted-by":"publisher","first-page":"e004699","DOI":"10.1136\/jitc-2022-004699","volume":"10","author":"LS Nguyen","year":"2022","unstructured":"Nguyen LS, Bretagne M, Arrondeau J, Zahr N, Ederhy S, Abbar B, et al. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: Proof of concept. J Immunother Cancer. 2022;10:e004699.","journal-title":"J Immunother Cancer"},{"key":"1947_CR132","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1465743","volume":"11","author":"Z Guan","year":"2024","unstructured":"Guan Z, Yao T, Liu G, Liu J, Guo L, Li Z, et al. Peripheral biomarkers to assess risk, severity, and prognosis of immune checkpoint inhibitor-associated myocarditis: a retrospective clinical study. Front Cardiovasc Med. 2024;11:1465743.","journal-title":"Front Cardiovasc Med"},{"key":"1947_CR133","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1093\/eurheartj\/ehaf1080","volume":"47","author":"EJ Song","year":"2026","unstructured":"Song EJ, Joachimbauer A, Tasca S, Baylis R, Schmidt D, Ludewig B, et al. T cells in acute and chronic myocarditis: from diagnosis to treatment. Eur Heart J. 2026;47:2255\u201370.","journal-title":"Eur Heart J"},{"key":"1947_CR134","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/ejhf.3636","volume":"27","author":"A Ghigo","year":"2025","unstructured":"Ghigo A, Ameri P, Asnani A, Bertero E, de Boer RA, Farmakis D, et al. Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC council of cardio-oncology, and the ESC working group on cellular biology of the heart. Eur J Heart Fail. 2025;27:1028\u201346.","journal-title":"Eur J Heart Fail"},{"key":"1947_CR135","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1677984","volume":"16","author":"S Feng","year":"2025","unstructured":"Feng S, Zhao B, Sha S, Bu X, Zhang Z, Liu G, et al. Overview of immune checkpoint inhibitor-associated myocarditis mechanisms diagnostics and treatment. Front Immunol. 2025;16:1677984.","journal-title":"Front Immunol"},{"key":"1947_CR136","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50996-5","volume":"15","author":"SJ Sun","year":"2024","unstructured":"Sun SJ, Jiao XD, Chen ZG, Cao Q, Zhu JH, Shen QR, et al. Gasdermin-E-mediated pyroptosis drives immune checkpoint inhibitor-associated myocarditis via cGAS-STING activation. Nat Commun. 2024;15:6640.","journal-title":"Nat Commun"},{"key":"1947_CR137","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009475","volume":"12","author":"L Cavalcante","year":"2024","unstructured":"Cavalcante L, Chandana S, Lakhani N, Enstrom A, LeBlanc H, Schmalz J, et al. Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1\/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab. J Immunother Cancer. 2024;12:e009475.","journal-title":"J Immunother Cancer"},{"key":"1947_CR138","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/imr.13262","volume":"318","author":"SM Blum","year":"2023","unstructured":"Blum SM, Rouhani SJ, Sullivan RJ. Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses. Immunol Rev. 2023;318:167\u201378.","journal-title":"Immunol Rev"},{"key":"1947_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115186","volume":"216","author":"D Tomsitz","year":"2025","unstructured":"Tomsitz D, Grabmaier U, Spiro J, Nicolai L, French LE, Massberg S, et al. Optimized monitoring for immune checkpoint inhibitor-induced myocarditis using high-sensitivity troponin-T. Eur J Cancer. 2025;216:115186.","journal-title":"Eur J Cancer"},{"key":"1947_CR140","doi-asserted-by":"crossref","unstructured":"Datta S, Banaskiewicz K, Yang Y-H, Olsson-Brown A. Utility of serial NT-proBNP measurement in the management of immune-checkpoint inhibitor-related myocarditis. 2025;5;111(Suppl 3):A7\u2013A9.","DOI":"10.1136\/heartjnl-2025-BCS.11"},{"key":"1947_CR141","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jaccao.2026.04.008","volume":"8","author":"D Daoudlarian","year":"2026","unstructured":"Daoudlarian D, Boughdad S, Bartolini R, Latifyan S, Doms J, Bouchaab H, et al. Immune profiling identifies inflammatory signatures in immune checkpoint inhibitor-related myocarditis. JACC Cardio-Oncol. 2026;8:245\u201362.","journal-title":"JACC Cardio-Oncol"},{"key":"1947_CR142","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jaccao.2026.05.003","volume":"8","author":"DA Zlotoff","year":"2026","unstructured":"Zlotoff DA, Rahman K, Blum SM. IL-6 in checkpoint myocarditis: a promising biomarker and therapeutic target. JACC Cardio-Oncol. 2026;8:263\u20135.","journal-title":"JACC Cardio-Oncol"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01947-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01947-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01947-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:19:31Z","timestamp":1790655571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01947-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":142,"alternative-id":["1947"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01947-x","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"5 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}